A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma

Inclusion Criteria:

• The participant (or legally acceptable representative [LAR], if applicable) provideswritten informed consent for the study.

• The participant is ≥22 years of age on the day of signing informed consent.

• The participant has clinical stage 1A2, 1A3 or IB biopsy-proven lung ADC and iseligible for anatomical resection.

• The participant has a lung nodule >1 cm and suspected lung ADC with a plan toundergo biopsy.

• The participant with multiple nodules has one nodule that meets the criteria.

• The participant has no history of prior malignancy in the chest or has undergonepotentially curative therapy with no evidence of that disease recurrence for 5 yearssince initiation of that therapy.

Exclusion Criteria:

• Patients receiving therapy for concurrent active malignancy

• Patients with a history of cardiac arrhythmias and/or pacemaker use

• Patients with lung nodules <1cm

• Patients with lung nodules that are pure ground glass opacities (GGOs) of any size

• Patients with lung nodules that are <50% solid of any size